812
Kojima et al.
23. S. L. Morissette, O. Almarsson, M. L. Peterson, J. F. Remenar,
M. J. Read, A. V. Lemmo, S. Ellis, M. J. Cima, and C. R.
Gardner. High-throughput crystallization: polymorphs, salts, co-
crystals and solvates of pharmaceutical solids. Adv. Drug Deliv.
Rev. 56:275Y300 (2004).
24. M. L. Peterson, S. L. Morissette, C. McNulty, A. Goldsweig,
P. Shaw, M. LeQuesne, J. Monagle, N. Encina, J. Marchionna,
A. Johnson, J. Gonzalez-Zugasti, A. V. Lemmo, S. J. Ellis, M. J.
Cima, and O. Almarsson. Iterative high-throughput polymor-
phism studies on acetaminophen and an experimentally derived
structure for form III. J. Am. Chem. Soc. 124:10958Y10959
(2002).
REFERENCES
1. A. J. Aguiar, J. Krc Jr., A. W. Kinkel, and J. C. Samyn. Effect of
polymorphism on the absorption of chloramphenicol from
chloramphenicol palmitate. J. Pharm. Sci. 56:847Y853 (1967).
2. J. W. Poole, G. Owen, J. Silverio, J. N. Freyhof, and S. B.
Rosenman. Physiochemical factors influencing the absorption of
the anhydrous and trihydrate forms of ampicillin. Curr. Ther.
Res. Clin. Exp. 10:292Y303 (1968).
3. M. Pudipeddi and A. T. Serajuddin. Trends in solubility of
polymorphs. J. Pharm. Sci. 94:929Y939 (2005).
4. Y. Matsuda and E. Tatsumi. Physicochemical characterization of
furosemide modifications. Int. J. Pharm. 60:11Y26 (1990).
5. C. Sun and D. J. Grant. Influence of crystal structure on the
tableting properties of sulfamerazine polymorphs. Pharm. Res.
18:274Y280 (2001).
6. M. Otsuka, H. Hasegawa, and Y. Matsuda. Effect of poly-
morphic transformation during the extrusion-granulation pro-
cess on the pharmaceutical properties of carbamazepine
granules. Chem. Pharm. Bull. (Tokyo) 45:894Y898 (1997).
7. L. X. Yu, R. A. Lionberger, A. S. Raw, R. D’Costa, H. Wu, and
A. S. Hussain. Applications of process analytical technology to
crystallization processes. Adv. Drug Deliv. Rev. 56:349Y369 (2004).
8. S. R. Chemburkar, J. Bauer, K. Deming, H. Spiwek, K. Patel, J.
25. J. F. Remenar, J. M. MacPhee, B. K. Larson, V. A. Tyagi, and
J. H. Ho. Salt selection and simultaneous polymorphism
assessment via high-throughput crystallization: the case of
sertraline. Org. Process Res. Dev. 7:990Y996 (2003).
26. O. Almarsson, M. B. Hickey, M. L. Peterson, S. L. Morissette,
S. Soukasene, and C. McNulty. High-throughput surveys of
crystal form diversity of highly polymorphic pharmaceutical
compounds. Cryst. Growth Des. 3:927Y933 (2003).
27. E. C. Ware and D. R. Lu. An automated approach to salt
selection for new unique trazodone salts. Pharm. Res. 21:177Y184
(2004).
28. P. J. Desrosiers. The potential of preform. Mod. Drug Discov.
7:40Y43 (2004).
Morris, and R. Henry. Dealing with the impact of ritonavir 29. E. D. Carlson, P. Cong, W. H. Chandler, H. K. Chau, T. Crevier,
polymorphs on the late stages of bulk drug process development.
Org. Process Res. Dev. 4:413Y417 (2000).
P. J. Desrosiers, R. D. Doolen, C. Freitag, L. A. Hall, T. Kudla,
R. Luo, C. Masui, J. Rogers, L. Song, A. Tangkilisan, K. Q. Ung,
and L. Wu. An integrated high throughput workflow for pre-
formulations: polymorph and salt selection studies. Pharma.
Chem. 10Y15 (2003).
9. J. Bauer, S. Spanton, R. Henry, J. Quick, W. Dziki, W. Porter,
and J. Morris. Ritonavir: an extraordinary example of confor-
mational polymorphism. Pharm. Res. 18:859Y866 (2001).
10. K. Knapman. Polymorphic predictions. Mod. Drug Discov.
3:53 Y54, 57 (2000).
11. J. O. Henck, J. Bernstein, A. Ellern, and R. Boese. Disappearing
and reappearing polymorphs. The benzocaine:picric acid system.
J. Am. Chem. Soc. 123:1834Y1841 (2001).
30. M. E. Auer, U. J. Griesser, and J. Sawatzki. Qualitative and
quantitative study of polymorphic forms in drug formulations by
near infrared FT-Raman spectroscopy. J. Mol. Struct. 661Y
662:307Y317 (2003).
31. W. P. Findlay and D. E. Bugay. Utilization of Fourier
transformYRaman spectroscopy for the study of pharmaceu-
tical crystal forms. J. Pharm. Biomed. Anal. 16:921Y930
(1998).
12. S. Byrn, R. Pfeiffer, M. Ganey, C. Hoiberg, and G. Poochikian.
Pharmaceutical solids: a strategic approach to regulatory con-
siderations. Pharm. Res. 12:945Y954 (1995).
13. G. L. Engel, N. A. Farid, M. M. Faul, L. A. Richardson, and L. L. 32. G. Barr, W. Dong, and C. J. Gilmore. PolySNAP: a computer
Winneroski. Salt form selection and characterization of LY333531
program for analyzing high-throughput powder diffraction data.
mesylate monohydrate. Int. J. Pharm. 198:239Y247 (2000). J. Appl. Crystallogr. 37:658Y664 (2004).
14. R. J. Bastin, M. J. Bowker, and B. J. Slater. Salt selection and 33. C. J. Gilmore, G. Barr, and J. Paisley. High-throughput powder
optimization procedures for pharmaceutical new chemical
entities. Org. Process Res. Dev. 4:427Y435 (2000).
15. P. L. Gould. Salt selection for basic drugs. Int. J. Pharm.
33:201Y217 (1986).
16. K. R. Morris, M. G. Fakes, A. B. Thakur, A. W. Newman, and
diffraction. I. A new approach to qualitative and quantitative
powder diffraction pattern analysis using full pattern profiles.
J. Appl. Crystallogr. 37:231Y242 (2004).
34. I. Ivanisevic, D. E. Bugay, and S. Bates. On pattern matching of
X-ray powder diffraction data. J. Phys. Chem. B. 109:7781Y7787
(2005).
A. K. Singh. An integrated approach to the selection of optimal
salt form for a new drug candidate. Int. J. Pharm. 105:209Y217 35. A. U. Buzdar. Tamoxifen’s clinical applications: old and new.
(1994). Arch. Fam. Med. 9:906Y912 (2000).
17. W. Q. Tong and G. Whitesell. In situ salt screeningYa useful 36. I. Goldberg and Y. Becker. Polymorphs of tamoxifen citrate:
technique for discovery support and preformulation studies.
detailed structural characterization of the stable form. J. Pharm.
Pharm. Dev. Technol. 3:215Y223 (1998).
18. S. L. Childs, L. J. Chyall, J. T. Dunlap, V. N. Smolenskaya, B. C. 37. J. Breitenbach, W. Schrof, and J. Neumann. Confocal Raman-
Sci. 76:259Y264 (1987).
Stahly, and G. P. Stahly. Crystal engineering approach to
forming cocrystals of amine hydrochlorides with organic acids.
Molecular complexes of fluoxetine hydrochloride with benzoic, 38. F. C. Clarke, M. J. Jamieson, D. A. Clark, S. V. Hammond,
spectroscopy: analytical approach to solid dispersions and
mapping of drugs. Pharm. Res. 16:1109Y1113 (1999).
succinic, and fumaric acids. J. Am. Chem. Soc. 126:13335Y13342
(2004).
19. S. L. Price. The computational prediction of pharmaceutical
crystal structures and polymorphism. Adv. Drug Deliv. Rev.
56:301Y319 (2004).
R. D. Jee, and A. C. Moffat. Chemical image fusion. The
synergy of FT-NIR and Raman mapping microscopy to
enable a more complete visualization of pharmaceutical
formulations. Anal. Chem. 73:2213Y2220 (2001).
39. D. E. Bugay. Characterization of the solid-state: spectroscopic
techniques. Adv. Drug Deliv. Rev. 48:43Y65 (2001).
20. C. H. Gu, H. Li, R. B. Gandhi, and K. Raghavan. Grouping
solvents by statistical analysis of solvent property parameters: 40. D. Giron. Characterisation of salts of drug substances. J. Therm.
implication to polymorph screening. Int. J. Pharm. 283:117Y125
(2004).
Anal. Calorim. 73:441Y457 (2003).
41. S. G. Fleischman, S. S. Kuduva, J. A. McMahon, B. Moulton,
B. W. R. D., N. Rodriguez-Hornedo, and M. J. Zaworotko.
Crystal engineering of the composition of pharmaceutical
phases: multiple-component crystalline solids involving car-
bamazepine. Cryst. Growth Des. 3:909Y919 (2003).
21. C. H. Gu, V. Young Jr., and D. J. Grant. Polymorph screening:
influence of solvents on the rate of solvent-mediated poly-
morphic transformation. J. Pharm. Sci. 90:1878Y1890 (2001).
22. S. L. Morissette, S. Soukasene, D. Levinson, M. J. Cima, and
O. Almarsson. Elucidation of crystal form diversity of the HIV 42. A. V. Trask, W. D. Motherwell, and W. Jones. Solvent-drop
protease inhibitor ritonavir by high-throughput crystallization.
grinding: green polymorph control of cocrystallisation. Chem.
Commun. (Camb.) 890Y891 (2004).
Proc. Natl. Acad. Sci. USA 100:2180Y2184 (2003).